<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[International Journal of Ophthalmology Press -->Commentary]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New ideas for medical therapy of glaucoma in the future]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200804001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[New drugs are developed rapidly with novel ideas of action
mechanisms for the treatment of glaucoma. The most classic
drugs under development are to lower the intraocular
pressure (IOP). New agents were invented to lower the IOP
through ① induction of metalloproteinases (MMPs), ②
contraction of trabecular meshwork cells, ③ inhibition of
aqueous humor secretion, and ④ activation of CB-1 receptor,
The second class of drugs under development is intended
to improve the ocular blood flow (OBF), particularly in retina
and optic nerve head (ONH). Drugs that improve the OBF
irrespective of the IOP changes could be quite useful for the
treatment of normal tension or low-tension glaucoma.
Neuroprotection is the latest developed mechanisms of
glaucoma treatment. Although the history of neuroprotection
research is very short, there are many agents under
investigation in this class. They include ① blockade of
N-methyl-D-aspartate receptor, ② neurotrophic agents, ③
inhibition of inducible nitric oxide synthases (iNOS), ④
inhibition of apoptosis, ⑤ protective autoimmunity, ⑥ stem
cell therapy, and so on. Since all drugs for glaucoma
treatment are used to stabilize the disease rather than to cure
it, it is critical that an ideal drug with high therapeutic index
and low cost price should be invented.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Y H Zou and George C Y Chiou]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Y H Zou and George C Y Chiou</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200804001]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Keratorefractive surgery and glaucoma]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200803001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Keratorefractive surgery changesthe central cornealthickness (CCT) and corneal curvature, which could influencethe Goldmann aPPlanationtonometer (GAT) and non-contacttonometer (NCT) measurementsof intraocular Pressure (IOP), but not dynamic contourtonometer(DCT). Duringthe Procedureof LASIK,there is atransient riseof IOP, which increasesthe risksofoPtic nerve damage. Meanwhile,the Presenceof functioning filtering blebs may affectthe choice andoutcomeof refractive surgery,or even becomes a contraindicationof surgery. Steroids aretyPically used after keratorefractive surgery, which could leadto IOP elevation. Hence it is imPortantto monitor IOP after LASIK andto be awareof inaccurate IOP readings dueto corneal flaP interface fluid.treating Patients with PostoPerative elevated IOP after keratorefractive surgery is similartothat for Patients with glaucoma.this review will addressthe issues surroundingthe safety, relevant comPlications and imPlicationsof keratorefractive surgerieson glaucoma and relevant diagnostictests.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Xuan Zou,Xuan-Chu Duan,Ning Xia,Mei-Ping Wang and Jian Shen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xuan Zou,Xuan-Chu Duan,Ning Xia,Mei-Ping Wang and Jian Shen</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200803001]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development of age-related macular degeneration experimental models]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200903001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[We reviews different experimental models of age-related macular degeneration (AMD) used in recent studies. The most widely used one is Laser-induced choroidal neovascularization (CNV), which represents the late severe stage in the exudative form of AMD. Other models are based on several different pathogenesis, like geographic atrophy, drusen formation or multifactorial effects, like age, light, high fat, etc. It is hoped that this article could become a good reference for researchers who need to choose suitable models for AMD study.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Wei Jiang and George C Y Chiou]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Wei Jiang and George C Y Chiou</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200903001]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[HIV/AIDS and ocular complications]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200902001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The introduction of highly active antiretroviral therapy (HAART) has greatly changed the pattern and natural history of ocular diseases of HIV-infected patients, resulting from the immune recovery and reduction of opportunistic infections. However, ophthalmic complication continues to be concern in AIDS even in the HAART era, especially in developing areas, where absolute majority of HIV-positive patients live. Lack of test facilities and experience, poor conditions of hygiene, different microbiological environment, absence of effective treatment etc., characterize the ophthalmic manifestation of HIV-infected patients in developing countries from that in developed regions and thus pose a great challenge to the ophthalmic treatment in developing area. Not only varied from region to region, ocular complications are distinctive between adults and children. At the same time, the side effects due to the application of HAART pose their own risks of ocular comp- lication and should, therefore, be given more resear]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Sui-Yi Tan,Shu-Wen Liu and Shi-Bo Jiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Sui-Yi Tan,Shu-Wen Liu and Shi-Bo Jiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200902001]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Susceptibility genes for diabetic retinopathy]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200901001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic retinopathy (DR) is a sight-threatening chronic complication of diabetes mellitus and is the leading cause of acquired blindness in adults. Long-term exposure to the hyperglycemia of diabetes patients leads to the development of DR. Several studies have provided evidence that good diabetes control is important to prevent DR. However, emerging evidence suggests that genes are a significant contributor to an individual's risk of retinopathy. This evidence is from evalu- ations of familial aggregation and different incidence of DR in racial and ethnic groups. Some groups of patients develop DR despite good control and some escape retinopathy despite poor control. This suggests that the genes are involved in the susceptibility to DR. Genes suggested as having a role include those encoding aldose reductase, nitric oxide synthase, receptor for advanced glycation end products, angiotensin converting enzyme, vascular endothelial growth factors and pigment epithelium-derived factor. An understanding of the role of susceptibility genes will ultimately allow the development of novel therapeutic strategies. This article reviews the role of genetic factors in the etiology and progression of DR.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Juan Li and Yong-Hua Hu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Juan Li and Yong-Hua Hu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/200901001]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Neuroprotection of retinal ganglion cells with GDNF-Loaded biodegradable microspheres in experimental glaucoma]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201003001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glaucoma is the second leading cause of blindness worldwide, and also the most common optic neuropathy. The ultimate cause of vision loss in glaucoma is thought to be retinal ganglion cell (RGC) death. Neuroprotection of RGC is therefore an important goal of glaucoma therapy. Currently, glaucoma treatment relies on pharmacologic or surgical reduction of intraocular pressure (IOP). It is critical to develop treatment approaches that actively prevent the death of RGCs at risk in glaucoma. Neurotrophic factors have the ability to promote the survival and influence the growth of neurons. Neurotrophic factor deprivation has been proposed as one mechanism leading to RGC death in glaucoma. Effective neuroprotection in glaucoma likely requires the consistent availability of the active agent for prolonged periods of time. Biodegradable microspheres are especially attractive as drug delivery vehicles for a number of reasons. Sustained GDNF delivery by biodegradable microspheres offers significant neuroprotection to injured RGC in experimental glaucoma. PLGA microsphere-delivered GDNF represents an important neuroprotective strategy in the treatment of glaucomatous optic neuropathy and provides direction for further investigations of this hypothesis.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Jian-He Xiao and Mao-Nian Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jian-He Xiao and Mao-Nian Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201003001]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Spontaneous rodent models of diabetes and diabetic retinopathy]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201001001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[ Diabetes is a complex and heterogeneous disorder presently affecting more than 100 million people worldwide and causing serious socio-economic problems. Spontaneous rodent models of diabetes mellitus have proved invaluable in understanding the pathogenesis, complications, and genetic or environmental influences that increase the risks of diabetes. We have reviewed here in the development and characterization of spontaneous rodent models that displayed most features commonly associated with diabetic retinopathy.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Cai-Rui Li and Shu-Guang Sun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Cai-Rui Li and Shu-Guang Sun</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201001001]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[TRPC6: an underlying target for human glaucoma]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201204023]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glaucoma is one of the leading causes of visual impairment and blindness worldwide. Of known risk factors for glaucoma, an increased in intraocular pressure is most highly correlated with glaucomatous damage. Irrespective of the cause, apoptosis of the retinal ganglion cells is the eventual outcome. It is widely accepted that glaucoma is a neurodegenerative disease that is strongly correlated with central nervous system disorders, such as Alzheimer’s disease. These two disorders also share some similarities in pathogenic mechanisms. Recent studies suggest that the transient receptor potential canonical 6 channel could work together with brain-derived neurotrophic factor to promote neuron survival in brain and retina. In this study, we propose that transient receptor potential canonical 6 may contribute to the pathogenesis of human glaucoma and become a potential therapeutic target.]]></description>
<pubDate></pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Qian Fan,Wen-Bin Huang and Xiu-Lan Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Qian Fan,Wen-Bin Huang and Xiu-Lan Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201204023]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Unmasking the mask: the role of personal protective equipment for ophthalmologists caring for asymptomatic patients during the COVID-19 pandemic]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20201201]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The use of personal protective equipment (PPE) for ophthalmologists caring for asymptomatic patients remains controversial. This commentary reviews the latest emerging evidence. This is paramountly important in shaping health policies in countries which is not currently recommended.]]></description>
<pubDate>2020/10/21 0:00:00</pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Adrian T. Fung]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Adrian T. Fung</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20201201]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Intraocular lens removal or not during vitrectomy for acute infectious endophthalmitis after cataract surgery]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20220601]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[At present, the incidence of infectious endophthalmitis after cataract surgery has been significantly reduced, but it is still a serious complication. Removal or not of the intraocular lens (IOL) during vitrectomy in cases with a moderate or severe inflammation is controversial. In order to call upon more discussion, we publish the article entitled “Timely vitrectomy without intraocular lens removal for acute endophthalmitis after cataract surgery” written by Guo et al in this issue. With recent advanced vitrectomy techniques, and critical measures for management of risk factors related to occurrence of infection, IOL remaining during timely vitrectomy for acute endophthalmitis can possibly be safe and effective in selected cases.]]></description>
<pubDate>2022/5/31 14:47:06</pubDate>
<category><![CDATA[Commentary]]></category>
<author><![CDATA[Yan-Nian Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Nian Hui</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20220601]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>